ADAlexander Dhaliwal

Alexander Dhaliwal

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Alexander Dhaliwal has a total of 28 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Quantitative Pharmacokinetics Reveal Impact of Lipid Composition on Microbubble and Nanoprogeny Shell Fate

    by Maneesha A. Rajora, Alexander Dhaliwal, Mark Zheng, Victor Choi, Marta Overchuk, Jenny W. H. Lou, Carly Pellow, David Goertz, Juan Chen, Gang Zheng

    Microbubble‐enabled focused ultrasound (MB‐FUS) has revolutionized nano and molecular drug delivery capabilities. Yet, the absence of longitudinal, systematic, quantitative studies of microbubble shell pharmacokinetics hinders progress within the MB‐FUS field. Microbubble radiolabeling challenges contribute to this void. This barrier is overcome by developing a one‐pot, purification‐free copper chelation protocol able to stably radiolabel diverse porphyrin‐lipid‐containing Definity® analogues (pDefs) with >95% efficiency while maintaining microbubble physicochemical properties. Five tri‐modal (ultrasound‐, positron emission tomography (PET)‐, and fluorescent‐active) [64Cu]Cu‐pDefs are created with varying lipid acyl chain length and charge, representing the most prevalently studied microbubble compositions. In vitro, C16 chain length microbubbles yield 2–3x smaller nanoprogeny than C18 microbubbles post FUS. In vivo, [64Cu]Cu‐pDefs are tracked in healthy and 4T1 tumor‐bearing mice ± FUS over 48 h qualitatively through fluorescence imaging (to characterize particle disruption) and quantitatively through PET and γ‐counting. These studies reveal the impact of microbubble composition and FUS on microbubble dissolution rates, shell circulation, off‐target tissue retention (predominantly the liver and spleen), and FUS enhancement of tumor delivery. These findings yield pharmacokinetic microbubble structure‐activity relationships that disrupt conventional knowledge, the implications of which on MB‐FUS platform design, safety, and nanomedicine delivery are discussed.


  • Open Access

    Nanostructure‐Driven Indocyanine Green Dimerization Generates Ultra‐Stable Phototheranostics Nanoparticles

    by Nahyun Kwon, Gabriel O. Jasinevicius, Giulia Kassab, Lili Ding, Jiachuan Bu, Letícia P. Martinelli, Vinicius G. Ferreira, Alexander Dhaliwal, Harley H. L. Chan, Yulin Mo, et al.

    Indocyanine green (ICG) is the only near‐infrared (NIR) dye approved for clinical use. Despite its versatility in photonic applications and potential for photothermal therapy, its photobleaching hinders its application. Here we discovered a nanostructure of dimeric ICG (Nano‐dICG) generated by using ICG to stabilize nanoemulsions, after which ICG enabled complete dimerization on the nanoemulsion shell, followed by J‐aggregation of ICG‐dimer, resulting in a narrow, red‐shifted (780 nm→894 nm) and intense (≈2‐fold) absorbance. Compared to ICG, Nano‐dICG demonstrated superior photothermal conversion (2‐fold higher), significantly reduced photodegradation (−9.6 % vs. −46.3 %), and undiminished photothermal effect (7 vs. 2 cycles) under repeated irradiations, in addition to excellent colloidal and structural stabilities. Following intravenous injection, Nano‐dICG enabled real‐time tracking of its delivery to mouse tumors within 24 h by photoacoustic imaging at NIR wavelength (890 nm) distinct from the endogenous signal to guide effective photothermal therapy. The unprecedented finding of nanostructure‐driven ICG dimerization leads to an ultra‐stable phototheranostic platform.


  • Open Access

    Nanostructure‐Driven Indocyanine Green Dimerization Generates Ultra‐Stable Phototheranostics Nanoparticles

    by Nahyun Kwon, Gabriel O. Jasinevicius, Giulia Kassab, Lili Ding, Jiachuan Bu, Letícia P. Martinelli, Vinicius G. Ferreira, Alexander Dhaliwal, Harley H. L. Chan, Yulin Mo, et al.

    Indocyanine green (ICG) is the only near‐infrared (NIR) dye approved for clinical use. Despite its versatility in photonic applications and potential for photothermal therapy, its photobleaching hinders its application. Here we discovered a nanostructure of dimeric ICG (Nano‐dICG) generated by using ICG to stabilize nanoemulsions, after which ICG enabled complete dimerization on the nanoemulsion shell, followed by J‐aggregation of ICG‐dimer, resulting in a narrow, red‐shifted (780 nm→894 nm) and intense (≈2‐fold) absorbance. Compared to ICG, Nano‐dICG demonstrated superior photothermal conversion (2‐fold higher), significantly reduced photodegradation (−9.6 % vs. −46.3 %), and undiminished photothermal effect (7 vs. 2 cycles) under repeated irradiations, in addition to excellent colloidal and structural stabilities. Following intravenous injection, Nano‐dICG enabled real‐time tracking of its delivery to mouse tumors within 24 h by photoacoustic imaging at NIR wavelength (890 nm) distinct from the endogenous signal to guide effective photothermal therapy. The unprecedented finding of nanostructure‐driven ICG dimerization leads to an ultra‐stable phototheranostic platform.


  • Prolonged Circulating Lipid Nanoparticles Enabled by High-Density Gd-DTPA-Bis(stearylamide) for Long-Lasting Enhanced Tumor Magnetic Resonance Imaging

    by Denis A. Margalik, Juan Chen, Tiffany Ho, Lili Ding, Alexander Dhaliwal, Andrea S. Doria, Gang Zheng

    Porphysomes (PS) were explored to incorporate different types of diethylenetriaminepentaacetic-acid-gadolinium-(III) (Gd-DTPA)-lipids into their bilayer membrane to assess PS potential as an MRI contrast agent. The Gd-dPS-BSA by integration of over 30% Gd-DTPA-bis(stearylamide) (Gd-DTPA-BSA)-lipids in PS construction resulted in exceptional serum stability and T1 and T2 relaxivity measurements of 13 mM-1 s-1 and 19 mM-1 s-1, respectively. The Gd-dPS-BSA demonstrated significantly enhanced retention in blood circulation with a half-life of 13.6 h and high tumor accumulation up to 19.5%ID/g at 72 h post-injection in select cancer mouse models. Additionally, Gd-dPS-BSA displayed excellent MRI tumor enhancement over 24, 48, and 72 h with contrast enhancements from the baseline of 35.8%, 38.2%, and 38.3%, respectively. Results reported here highlight a high-density incorporation of Gd-DTPA-BSA-lipids within PS, and other liposome formulations can enhance circulatory longevity, independently of particles' concentration, suggesting effective MRI contrast agent potential for Gd-dPS-BSA and potential utility of Gd-DTPA-BSA-lipids to enhance other liposomal-influenced diagnostic and therapeutic functions.


  • Open Access

    Synthesis and Characterization of Multi-Modal Phase-Change Porphyrin Droplets

    by Kimoon Yoo, Alexander Dhaliwal, Juan Chen, Paul S. Sheeran, Gang Zheng

    Phase-change droplets are a class of ultrasound contrast agents that can convert into echogenic microbubbles in situ with the application of sufficient acoustic energy. Droplets are smaller and more stable than their microbubble counterparts. However, traditional ultrasound contrast agents are not trackable beyond acoustic feedback measurements, which makes quantifying contrast agent bio-distribution or accumulation ex vivo difficult. Researchers may have to rely on fluorescent or optically absorbent companion diagnostic particles to infer bio-distribution. The purpose of this protocol is to detail steps for creating multi-modal phase-change porphyrin droplets using a condensation method. Porphyrins are fluorescent molecules with distinct absorbance bands that can be conjugated onto lipids and incorporated into droplets to extend droplet versatility, enabling more robust bio-distribution while retaining acoustic properties. Seven formulations with varying porphyrin-lipid and base lipid contents were made to investigate microbubble and droplet size distributions. Characterizations suited to porphyrin-containing structures are also described in the protocol to demonstrate their analytic versatility in-solution. Sizing showed that the post-condensed mean diameters were 1.72 to 2.38 times smaller than precursor populations. Absorbance characterization showed intact assemblies had a Q-band peak of 700 nm while disrupted samples had an absorbance peak at 671 nm. Fluorescence characterization showed intact 30% porphyrin-lipid assemblies were fluorescently quenched (>97%), with fluorescence recovery achieved upon disruption. Acoustic vaporization showed that porphyrin droplets were non-echogenic at lower pressures and could be converted into echogenic microbubbles with sufficient pressures. These characterizations show the potential for porphyrin droplets to eliminate the need for absorbance or fluorescence-based companion diagnostic strategies to quantify ultrasound contrast agent bio-distribution for delivery or therapeutic applications in vivo or ex vivo.